GlassScriptPhysician profile
Rosivel Flores
NPI 1881238087
$2,609.23
in general payments reported to CMS, 2019-2025
21 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.52 · 2024: $598 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $300.42 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Biotronik Nro, INC. | $299.04 | 2025 | Prospera |
| Abbvie INC. | $235.51 | 2024-2025 | |
| Boston Scientific Corporation | $206.40 | 2025 | General - Pain Management, Intracept |
| Vertos Medical, INC. | $163.11 | 2024 | Mild Device Kit |
| Csl Behring | $158.54 | 2024 | Kcentra |
| Baxter Healthcare | $150.00 | 2025 | Tisseel, Floseal |
| Averitas Pharma INC. | $139.43 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $139.33 | 2024-2025 | |
| Mml US, INC. | $128.75 | 2025 | Reactiv8 |
| Pfizer INC. | $125.00 | 2025 | |
| Valinor Pharma, LLC | $94.07 | 2024-2025 | Movantik |
| Forte Bio-Pharma LLC | $84.68 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Axsome Therapeutics, INC. | $81.96 | 2025 | Symbravo |
| Protega Pharmaceutials INC | $73.18 | 2025 | Roxybond |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $70.40 | 2024-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.93 | 2025 | Relistor |
| Collegium Pharmaceutical, INC. | $44.32 | 2025 | Belbuca |
| Convatec INC. | $23.17 | 2024 | |
| Tersera Therapeutics LLC | $17.47 | 2025 | Prialt |
| Janssen Pharmaceuticals, INC | $13.52 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosivel Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.